Canadian Rheumatology Association Position Statement on Criteria for Access to Targeted Agents for Rheumatoid Arthritis in Canada

There are currently significant discrepancies between Canadian provinces and territories in the criteria for access to advanced targeted agents for rheumatoid arthritis (RA) treatment. Such targeted agents include biologic medications as well as small molecule inhibitors. In hopes of supporting universality and equity of care for rheumatoid arthritis patients in Canada, the Canadian Rheumatology Association Therapeutics Committee has reviewed the current provincial and territorial criteria (see Addendum) and makes the following recommendations for criteria to access advanced targeted agents for treatment of RA, both for public and private payers.